Company
ReAlta Life Sciences
Targeting complement and neutrophils, our platform delivers broad long-lasting control of inflammation with a differentiated clinical profile
Also known as ReAlta Life Sciences, Inc.
- Status
- Operatingas of 2026-09-18
- Business model
- B2B
- Headquarters
- Norfolk, VA, United States
- Legal name
- ReAlta Life Sciences, Inc.
- realtalifesciences.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- Press page (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
ReAlta Life Sciences is clinically advancing a first-in-class, disease-modifying therapy targeting multiple upstream pathological drivers of inflammation in serious medical diseases.
Funding snapshot
- Total raised
- $94.3MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Undisclosed, $40M2026-04-08
Funding rounds
- Round, 2026
- $40M2026-04-08, Company stated
- Round, 2024
- $25M2024-12-18, SEC form D sold, 109 investors
- Round, 2023
- $29.9M2023-11-07, SEC form D sold, 149 investors
- Round, 2023
- $12M2023-02-22, SEC form D sold, 85 investors
- Round, 2020
- $22.5M2020-12-18, SEC form D sold, 92 investors
- Round, 2020
- 2020-02-19
- Round, 2019
- 2019-10-28
- Round, 2018
- $4.8M2018-09-10, SEC form D sold, 1 investor
Products
- Other
- Pegtarazimod
Loading relationship preview